Executive Vice President, Business Development & Alliance Management, Bioverativ
Richard Brudnick is Executive Vice President for Business Development & Alliance Management at Bioverativ, the newly formed, independent and publicly traded spinoff from Biogen of its hemophilia and blood disorders business.. During his years with Biogen, Richard was responsible for business development transactions which have resulted in several of Biogen’s marketed and late stage products, including TECFIDERA, ZINBRYTA, ELOCTATE, ALPROLIX, BENEPALI, FLIXABI, SPINRAZA and raxatrigine as well as its joint venture with Samsung to develop and commercialize biosimilar products. Before joining Biogen, Richard was CEO of a regional pharmaceutical distribution business which he sold to a strategic buyer, co-founded two companies, and was a strategy consultant at Bain & Company. He earned his undergraduate and graduate degrees at MIT. Richard enjoys boating, scuba diving, blues music, and spending time with his wife and three sons. He also enjoys history and reading the biographies of people who lived through and shaped the events which help define our times.